Immunomodulatory nanodiamond aggregate-based platform for the treatment of rheumatoid arthritis
- Immunomodulatory nanodiamond aggregate-based platform for the treatment of rheumatoid arthritis
- 권익찬; 김광명; 김민주; 고영지; 전상민; Amanda Pentecost; Yury Gogotsi; Kara L. Spiller
- Issue Date
- Regenerative biomaterials
- VOL 6, NO 3-174
- We previously demonstrated that octadecylamine-functionalized nanodiamond (ND-ODA) and
dexamethasone (Dex)-adsorbed ND-ODA (ND-ODA– Dex) promoted anti-inflammatory and proregenerative behavior in human macrophages in vitro. In this study, we performed a pilot study to investigate if these immunomodulatory effects translate when used as a treatment for rheumatoid arthritis in mice. Following local injection in limbs of mice with collagen type II-induced arthritis, microcomputed tomography showed that mice treated with a low dose of ND-ODA and ND-ODA– Dex did not experience bone loss to the levels observed in non-treated arthritic controls. A low dose of ND-ODA and ND-ODA– Dex also reduced macrophage infiltration and expression of proinflammatory mediators iNOS and tumor necrosis factor-a compared to the arthritic control, while a high dose of ND-ODA increased expression of these markers. Overall, these results suggest that ND-ODA may be useful as an inherently immunomodulatory platform, and support the need for an in-depth study, especially with respect to the effects of dose.
- Appears in Collections:
- KIST Publication > Article
- Files in This Item:
There are no files associated with this item.
- RIS (EndNote)
- XLS (Excel)
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.